CDSCO insights from 2026
This page lists every CDSCO insight dated 2026, 46 in all, from April 20, 2026 to November 10, 2026, newest first. Each headline opens our summary, which links to the regulator's own notice. The newest 24 are also shown as cards on the CDSCO insights page.
November 2026
- New adverse reactions for lithium, phenytoin and furosemide inserts
- Draft would bring all antimicrobials under the new drug definition
- Draft would let authorities relax Schedule M for medicinal gases
- Draft would make drug licensees comply with GSDP guidelines
- Draft adds a wholesale licence for bulk drugs, Form 20BC
October 2026
- Draft adds ICDs and Noida airport as drug import points
- Draft sets a no-growth limit for Grade A sterile areas
- Draft would require an authorized person for drug batch release
- Draft would suspend drug licences on NSQ reports until CAPA
- CDSCO asks states to enforce batch testing of drug raw materials
- High-risk solvent batches need an ONDLS NOC before distribution
- Final rule bars drug imports with under a year of shelf life left
- Approved r-DNA drugs exported under a new brand need no NOC
- CDSCO drafts a guide to IVD manufacturing licences
September 2026
August 2026
- Draft would add four drugs to Schedule H1
- All chlorpheniramine-phenylephrine FDCs need an under-4 warning
- Device labels to carry sterilization site licence number
- Device rules add EU countries to rule 63 and QMS for Class A
- CDSCO tells states to act on unapproved enclomiphene products
- New drugs approved nowhere go to CDSCO's IND Division
June 2026
- Cell and gene therapeutic products added to r-DNA licence rules
- Modified-release pellets and granules need CDSCO approval
- Vaccine and anti-sera post-approval changes move to SUGAM
- Draft sets shorter timelines for device manufacturing licences
- Draft would replace some drug test licences with prior intimation
- Draft would bar drug imports with under a year of shelf life left
- Schedule H2 to cover four drug categories from 2027 and 2028
- 16 fixed dose combinations banned for human use
- Cough syrups lose the Schedule K household remedies exemption
May 2026
- Imports for export BA/BE studies need a standalone CT-16 on NSWS
- New test fees for government drug laboratories
- CDSCO says injectable preparations are not cosmetics
- Pregabalin to join Schedule H1 of the Drugs Rules, 1945
- CDSCO and ethics committees to review trials in parallel
- CDSCO widens rejection of SUGAM applications awaiting replies